Emilia Scalzulli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib	ONCOLOGY AND THERAPY	2025
A novel complex mutation in the exon 9 of CALR gene: p.E381fs*52 (gagg_CCTCTTTGCCTC)	CURRENT RESEARCH IN TRANSLATIONAL MEDICINE	2025
CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut -AML): a flow-cytometric marker for an accurate diagnostic workup	LEUKEMIA & LYMPHOMA	2025
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib	HEMATOLOGICAL ONCOLOGY	2025
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	EUROPEAN JOURNAL OF HAEMATOLOGY	2024
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report	FRONTIERS IN ONCOLOGY	2024
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia	JOURNAL OF CLINICAL MEDICINE	2024
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response	JOURNAL OF CLINICAL MEDICINE	2024
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications	BRITISH JOURNAL OF HAEMATOLOGY	2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study	CANCER	2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	EXPERT OPINION ON DRUG SAFETY	2024
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors	EXPERT OPINION ON PHARMACOTHERAPY	2024
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia	CANCERS	2024
PROPENSITY SCORE MATCHING ANALYSIS COMPARING ASCIMINIB VERSUS PONATINIB FOR ITS TREATMENT OUTOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS	HEMASPHERE	2024
CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB	HEMASPHERE	2024
REVISED “IRR6” MODEL IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB	HEMASPHERE	2024
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION	HEMASPHERE	2024
MUTANT MYELOID GENE CATEGORY MAY PREDICT POOR RESPONSE TO JAK INHIBITORS IN PATIENTS WITH MYELOFIBROSIS	HEMASPHERE	2024
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)	EXPERT REVIEW OF HEMATOLOGY	2024
Case Report: Infectious prophylaxis in hematological malignancies	FRONTIERS IN ONCOLOGY	2023